BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Jarzebska NT, Mellett M, Frei J, Kündig TM, Pascolo S. Protamine-Based Strategies for RNA Transfection. Pharmaceutics 2021;13:877. [PMID: 34198550 DOI: 10.3390/pharmaceutics13060877] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 10.0] [Reference Citation Analysis]
Number Citing Articles
1 Jarzebska NT, Tusup M, Frei J, Weiss T, Holzinger T, Mellett M, Diken M, Bredl S, Weller M, Speck RF, Kündig TM, Sahin U, Pascolo S. RNA with chemotherapeutic base analogues as a dual-functional anti-cancer drug. OncoImmunology 2022;11. [DOI: 10.1080/2162402x.2022.2147665] [Reference Citation Analysis]
2 Gu Y, Duan J, Yang N, Yang Y, Zhao X. mRNA vaccines in the prevention and treatment of diseases. MedComm 2022;3. [DOI: 10.1002/mco2.167] [Reference Citation Analysis]
3 Uchida S. Delivery Systems of Plasmid DNA and Messenger RNA for Advanced Therapies. Pharmaceutics 2022;14:810. [DOI: 10.3390/pharmaceutics14040810] [Reference Citation Analysis]
4 Fu N, Li J, Wu J, Gao W, Zhang X, Shen B. Fabrication of ZIF-8 capsule with commodious microenvironment and synergistic effect for CBX@ZIF-8: Facilitating the detection of protamine. Dyes and Pigments 2022. [DOI: 10.1016/j.dyepig.2022.110340] [Reference Citation Analysis]
5 Fang E, Liu X, Li M, Zhang Z, Song L, Zhu B, Wu X, Liu J, Zhao D, Li Y. Advances in COVID-19 mRNA vaccine development. Signal Transduct Target Ther 2022;7:94. [PMID: 35322018 DOI: 10.1038/s41392-022-00950-y] [Cited by in Crossref: 18] [Cited by in F6Publishing: 23] [Article Influence: 18.0] [Reference Citation Analysis]
6 Hadianamrei R, Zhao X. Current state of the art in peptide-based gene delivery. Journal of Controlled Release 2022. [DOI: 10.1016/j.jconrel.2022.02.010] [Cited by in Crossref: 6] [Cited by in F6Publishing: 10] [Article Influence: 6.0] [Reference Citation Analysis]
7 Chen M, Hu X, Liu S. Next‐Generation Nonviral Vectors for mRNA Vaccine Delivery. Macro Chemistry & Physics. [DOI: 10.1002/macp.202100443] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
8 Faust A, Bäumer N, Schlütermann A, Becht M, Greune L, Geyer C, Rüter C, Margeta R, Wittmann L, Dersch P, Lenz G, Berdel WE, Bäumer S. Tumorzellspezifisches Targeting von Ibrutinib: Einführung von elektrostatischen Antikörper‐Inhibitor‐Konjugaten (AiCs). Angewandte Chemie 2022;134. [DOI: 10.1002/ange.202109769] [Reference Citation Analysis]
9 Thachil J. Protamine-The Journey from DNA to Heparin Neutralization to Gene therapy. Semin Thromb Hemost 2021. [PMID: 34729729 DOI: 10.1055/s-0041-1736574] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Faust A, Bäumer N, Schlütermann A, Becht M, Greune L, Geyer C, Rüter C, Margeta R, Wittmann L, Dersch P, Lenz G, Berdel WE, Bäumer S. Tumor-Cell-Specific Targeting of Ibrutinib: Introducing Electrostatic Antibody-Inhibitor Conjugates (AiCs). Angew Chem Int Ed Engl 2021. [PMID: 34725904 DOI: 10.1002/anie.202109769] [Reference Citation Analysis]